癌症治療基因組學市場－全球產業規模、佔有率、趨勢、機會和預測：按產品、技術、應用、最終用戶、地區和競爭對手分類，2021-2031年

全球癌症治療基因組學市場預計將大幅成長，從 2025 年的 167.9 億美元成長到 2031 年的 429.4 億美元，複合年成長率為 16.94%。

該市場專注於分析患者和腫瘤的基因譜，以透過標靶治療和個人化診斷策略來推進精準腫瘤學的發展。市場擴張的根本驅動力在於全球癌症發生率的不斷上升，這需要更先進的診斷工具，以及次世代定序(NGS) 技術成本的持續下降。例如，美國癌症協會預測，到 2025 年，美國將新增 2,041,910 例癌症病例，凸顯了基因組介入的迫切需求。基因測序成本的下降，得益於 Illumina 公司在 2023 年交付的 352 台 NovaSeq X 設備等技術的進步，使得臨床檢查室能夠更有效率地處理檢體，從而實現全面的基因組分析。此外，非侵入性液態生物檢體解決方案正在革新診斷領域，透過檢測循環腫瘤 DNA 實現早期發現和後續觀察。 Guardant Health 公司的 Shield 檢測就是一個例子，在結直腸癌檢測中達到了 83% 的靈敏度。鑑於世界衛生組織 (WHO) 預測 2050 年新增癌症病例將增加 77%，達到 3,500 萬例，這種便捷的取得途徑至關重要，並凸顯了擴充性篩檢工具的必要性。

市場促進因素

次世代定序(NGS) 技術的進步推動了基因測序成本的持續下降，這是市場成長的主要驅動力，使得高通量定序平台能夠更快、更有效率地處理基因樣本。這正在普及全面的基因組分析。例如，Illumina 在 2023 年交付了 352 台 NovaSeq X 定序儀，顯著提升了實驗室的基因測序能力，並降低了醫療機構將複雜基因組數據整合到常規腫瘤診療流程中的門檻。同時，非侵入性液態生物檢體解決方案的出現正在改變臨床診斷，為傳統的組織切片檢查提供了一種切實可行的替代方案。這些方案透過檢測循環腫瘤 DNA 來識別基因突變，從而實現早期發現和持續監測治療反應。據 Guardant Health 公司稱，其獲得 FDA已通過核准的Shield 檢測在結直腸癌檢測中展現出 83% 的靈敏度。正如世界衛生組織（世衛組織）在2024年報告的那樣，全球疾病負擔日益加重，預計到2050年，新增癌症病例將增加77%，達到3500萬例，因此，努力提高此類檢測的可及性至關重要。因此，液態生物檢體的擴充性直接滿足了對能夠服務於不斷成長的患者群體的大規模篩檢工具的需求。

市場挑戰

儘管成長勢頭強勁，但該市場仍面臨諸多挑戰。主要因素包括缺乏標準化的報銷政策以及全面基因組分析的高成本。保險公司之間缺乏統一的福利標準，導致醫療服務提供者面臨財務不確定性，從而在開立高級診斷測試時猶豫不決。這反過來又限制了關鍵基因數據的生成，並擾亂了臨床工作流程。這種經濟負擔直接影響患者，他們往往因為高昂的自付費用而被迫放棄建議的基因組分析測試。例如，根據美國癌症研究協會 (AACR) 的一份報告，美國超過 40% 的癌症患者在開始治療的兩年內耗盡了畢生積蓄。因此，患者獲得和接受基因組分析的比例較低，阻礙了基因組干預在標準癌症治療中的市場擴張和潛在收入成長。

市場趨勢

市場正受到變革性趨勢的雙重影響。人工智慧 (AI) 與基因組工作流程的融合，實現了大量資料集分析的自動化，並有助於識別可操作的腫瘤生物標記。這消除了人工審查突變數據的瓶頸，使研究人員能夠有效地將複雜的基因譜與治療結果關聯起來。隨著檢查室尋求拓展精準腫瘤學業務，這種商業性動能尤其顯著。由於其人工智慧驅動的基因組學平台的廣泛應用，Tempus AI 預計 2024 年全年銷售額將達到 6.934 億美元，同比成長 30.4%，這凸顯了人們越來越依賴計算工具來提高診斷的速度和準確性。同時，長讀長定序技術的出現已被證明對於檢測傳統短讀長定序平台常常忽略的複雜結構突變至關重要。這些系統能夠對長 DNA 區域定序而不會發生片段化，從而更全面地整體情況腫瘤異質性和融合基因，而這些對於標靶治療方案的發展至關重要。牛津奈米孔技術公司的「PromethION」產品系列迅速採用了這項技術，2024 年的銷售額同比成長了 55.8%，這表明市場正在向原始生長讀能力強勁轉變，使臨床醫生能夠闡明對開發新型癌症治療方法至關重要的全面結構數據。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球基因體學市場在癌症治療領域的展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品（設備、耗材、服務）分類
  • 透過技術（基因測序、PCR、微陣列、核酸萃取和純化等）
  • 依應用領域（診斷、個人化醫療、藥物發現與開發、研究與發展）
  • 依最終使用者（醫院、研究機構/學術機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美癌症治療基因體學市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲癌症護理基因體學市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區癌症治療基因體學市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲癌症治療基因組學市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美癌症治療基因體學市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球癌症治療基因體學市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Illumina Inc
• Agilent Technologies, Inc.
• Roche Diagnostics
• Cancer Genetics, Inc.
• Bio-Rad Laboratories Inc
• Sigma-Aldrich Corp
• QIAGEN NV
• GE Healthcare Inc
• Life Technologies Corp
• Quest Diagnostics Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Genomics in Cancer Care Market is projected for substantial growth, expanding from USD 16.79 Billion in 2025 to USD 42.94 Billion by 2031, at a robust 16.94% CAGR. This market focuses on analyzing patient and tumor genetic profiles to guide precision oncology through targeted therapies and personalized diagnostic strategies. Its expansion is fundamentally driven by the escalating global incidence of oncological diseases, demanding advanced diagnostic tools, alongside the continuous reduction in costs associated with next-generation sequencing (NGS) technologies. For instance, the American Cancer Society projects 2,041,910 new cancer cases in the United States in 2025, underscoring the critical need for genomic interventions. The declining costs of genome sequencing, propelled by advancements like the 352 NovaSeq X instruments shipped by Illumina in 2023, allow clinical laboratories to process samples more efficiently, thereby democratizing access to comprehensive genomic profiling. Complementing this, non-invasive liquid biopsy solutions are revolutionizing diagnostics by detecting circulating tumor DNA for early detection and monitoring, as demonstrated by Guardant Health's Shield test achieving 83% sensitivity for colorectal cancer detection. This accessibility is crucial given the World Health Organization's prediction of a 77% rise in new cancer cases to 35 million by 2050, highlighting the need for scalable screening tools.

Market Driver

The continuous reduction in genome sequencing costs, driven by advancements in Next-Generation Sequencing (NGS) technologies, serves as a primary engine for market growth by enabling high-throughput sequencing platforms to process genetic samples with greater speed and efficiency. This democratizes access to comprehensive genomic profiling, as evidenced by Illumina's shipment of 352 NovaSeq X instruments during 2023, which significantly scaled up genomic sequencing capabilities for laboratories and reduced the barrier to entry for healthcare facilities to integrate complex genomic data into routine oncology workflows. Simultaneously, the emergence of non-invasive liquid biopsy solutions is reshaping clinical diagnostics by offering a viable alternative to traditional tissue biopsies, detecting circulating tumor DNA to identify genetic mutations and facilitate early detection and continuous monitoring of treatment response. According to Guardant Health, its FDA-approved Shield test demonstrated 83% sensitivity for colorectal cancer detection. This shift toward accessible testing is crucial as the global burden of disease intensifies, with new cancer cases predicted to rise by 77% to reach 35 million by 2050, as reported by the World Health Organization in 2024. Consequently, the scalability of liquid biopsies directly addresses the need for mass screening tools capable of managing this increasing patient population.

Market Challenge

Despite this strong growth trajectory, the market faces significant impediments, primarily the lack of standardized reimbursement policies and the high costs associated with comprehensive genomic profiling. Inconsistent payer coverage criteria create financial uncertainty for healthcare providers, often leading to hesitation in ordering advanced diagnostic tests, which limits the generation of essential genetic data and disrupts clinical workflows. This economic burden extends directly to patients, with high out-of-pocket expenses often forcing them to decline recommended profiling, as exemplified by more than 40% of cancer patients in the United States exhausting their life savings within two years of treatment, according to the American Association for Cancer Research. Consequently, patient access and adoption rates are reduced, stifling market expansion and potential revenue growth for genomic interventions in standard cancer care.

Market Trends

The market is simultaneously being shaped by transformative trends. The integration of artificial intelligence (AI) into genomic workflows is automating the analysis of vast datasets to identify actionable oncological biomarkers, thereby addressing manual variant curation bottlenecks and allowing researchers to efficiently correlate complex genetic profiles with therapeutic outcomes. This commercial traction is significant as laboratories seek to scale precision oncology operations, with Tempus AI reporting full-year revenue of $693.4 million in 2024, representing a 30.4% year-over-year increase driven by the widespread adoption of its AI-enabled genomics platform, highlighting the growing reliance on computational tools for enhanced diagnostic speed and accuracy. Concurrently, the emergence of long-read sequencing technologies is proving essential for detecting complex structural variants often missed by traditional short-read platforms. These systems sequence long DNA stretches without fragmentation, providing a more complete picture of tumor heterogeneity and fusion genes critical for targeted treatment planning. The rapid adoption of this technology is evident in Oxford Nanopore Technologies' PromethION product range, which experienced a 55.8% year-over-year revenue growth in 2024, indicating a strong market shift toward native long-read capabilities that empower clinicians to uncover comprehensive structural data vital for developing novel cancer therapies.

Key Market Players

• Illumina Inc
• Agilent Technologies, Inc.
• Roche Diagnostics
• Cancer Genetics, Inc.
• Bio-Rad Laboratories Inc
• Sigma-Aldrich Corp
• QIAGEN NV
• GE Healthcare Inc
• Life Technologies Corp
• Quest Diagnostics Inc

Report Scope

In this report, the Global Genomics in Cancer Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomics in Cancer Care Market, By Product

• Instruments
• Consumables
• Services

Genomics in Cancer Care Market, By Technology

• Genome Sequencing
• PCR
• Microarray
• Nucleic Acid Extraction and Purification
• Others

Genomics in Cancer Care Market, By Application

• Diagnostics
• Personalized Medicine
• Drug Discovery & Development
• Research

Genomics in Cancer Care Market, By End User

• Hospitals
• Research Institutes & Academic Institutes
• Others

Genomics in Cancer Care Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genomics in Cancer Care Market.

Available Customizations:

Global Genomics in Cancer Care Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genomics in Cancer Care Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Consumables, Services)
  • 5.2.2. By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification, Others)
  • 5.2.3. By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research)
  • 5.2.4. By End User (Hospitals, Research Institutes & Academic Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Genomics in Cancer Care Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genomics in Cancer Care Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Genomics in Cancer Care Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Genomics in Cancer Care Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Genomics in Cancer Care Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genomics in Cancer Care Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Genomics in Cancer Care Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Genomics in Cancer Care Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Genomics in Cancer Care Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Genomics in Cancer Care Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Genomics in Cancer Care Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Genomics in Cancer Care Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Genomics in Cancer Care Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Genomics in Cancer Care Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Genomics in Cancer Care Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Genomics in Cancer Care Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Genomics in Cancer Care Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Genomics in Cancer Care Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Genomics in Cancer Care Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Genomics in Cancer Care Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Genomics in Cancer Care Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Genomics in Cancer Care Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Genomics in Cancer Care Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Genomics in Cancer Care Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Genomics in Cancer Care Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Illumina Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies, Inc.
• 15.3. Roche Diagnostics
• 15.4. Cancer Genetics, Inc.
• 15.5. Bio-Rad Laboratories Inc
• 15.6. Sigma-Aldrich Corp
• 15.7. QIAGEN NV
• 15.8. GE Healthcare Inc
• 15.9. Life Technologies Corp
• 15.10. Quest Diagnostics Inc

16. Strategic Recommendations

17. About Us & Disclaimer